First approval of the listing of autoimmune disease treatment will have domestic medicine

　　Pharmaceutical Network November 18, reporters from the State Drug Administration was informed that Adamu mono-anti-injection (commodity name: Greeli) listing registration application was recently approved This is the first approved Adamu mono biosimilar drug, indications for strong syllaline syllitis, rheumatoid arthritis and psoriasis and other autoimmune diseases according to the , Adamu mono-anti-injection is the world's first approved all-human source anti-
necrosis prosytophilia (TNF-thymoid) monoclonal antibody, which can specifically bind to soluble human TNF-thymoand and block its interaction with cell surface TNF receptor sp55 and p75, thus effectively blocking the inflammatory effect of TNF-thymo In addition, Adamu mono-resistance may also be combined with transmembrane TNF-thym, to produce induced apoptosis and other effects, to remove a part of the disease-causing target cells the approved Adamu mono-anti-injection is the first in China to the original research Adamu mono-anti-resistance as a reference drug, in accordance with the biosimilar drug approach to research and development and declaration of production products, and access to the national science and technology major new drug creation of major special support Through comprehensive qualitative similarity studies, non-clinical similarity studies and clinical comparison studies, the applicant ensures that the product is highly similar to the reference drug that has been approved for market The approval of this product will provide new options for patient treatment (Reporter Fu Lili)